Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome
Journal of Clinical Immunology · 06.08.2026 · 46 (1)
DOI: 10.1007/s10875-026-02056-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Immunology, online erschienen am 06.08.2026. Verfasst von Sara G Hamad und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Interferons, Macrophage Activation Syndrome. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sidra Medical and Research Center.
Abstract (Originalsprache)
Purpose
ZNFX1 interferes with early viral replication after exposure to type I interferon, and interacts with mitochondrial antiviral sensors (MAVS) leading to a balanced expression of interferon-stimulated genes (ISGs). ZNFX1 deficiency mimics systemic autoinflammatory diseases and accurate identification may prevent early mortality. We compare a homozygous ZNFX1 frameshift mutation patient to subjects with known interferonopathies. We explore the association between this mutation, unregulated ISGs, and macrophage activation syndrome (MAS).
Methods
Study participants included our index patient, other patients with well-characterized interferonopathies, and healthy participants. We performed western blotting for ZNFX1 and whole Blood mRNA-seq, RT-qPCR, ELISA, and Olink Proteomics analysis to assess cytokine production and the underlying immune dysregulation.
Results
Our patient had elevated expression of interferon-inducible genes compared to healthy controls, but levels were comparable to subjects with known interferonopathies. Gene sequencing revealed a novel homozygous ZNFX1 frameshift variant resulting in a truncated protein. Transcriptomic analysis pointed to the top 3 cytokine upstream regulators, tumor necrosis factor (TNF), IL-1β, and interferon-gamma. ZNFX1 deficient patients appear to have a clinical profile that differs from classical type I interferonopathies, including features such as thrombotic microangiopathy (TMA) and a higher frequency of MAS.
Conclusions
ZNFX1 deficiency is an immune dysregulation disorder characterized by a robust type I interferon signature combined with elevated inflammatory cytokines, leading to severe early-onset multisystem inflammatory disease. Characterizing the immune profile allows targeted short-term treatments that may prolong life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.
- Research Branch, Sidra Medicine, Doha, Qatar.
- Department of Pediatrics, Sidra Medicine, Doha, Qatar.
- Department of Pediatrics, Weill Cornell Medicine Qatar, Doha, Qatar.
- University of Qatar, Doha, Qatar.
- Institute of Epigenetics and Stem Cells, Helmholtz Zentrum München, Munich, Germany.
Förderung
- Sidra Medical and Research Center
Zitieren
APA
Hamad, S. G., Makhlouf, M., Agrebi, N., Kaddourah, A., Abu-Hasan, M., Al-Adba, B., Sadoun, A., Hubrack, S. Z., Aamer, W., Segura, M. L. R. T., Scialdone, A., Machaca, K., Saraiva, L. R., Bout-Tabaku, S., & Lo, B. (2026). Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome. Journal of Clinical Immunology, 46(1). https://doi.org/10.1007/s10875-026-02056-4
Vancouver
Hamad SG, Makhlouf M, Agrebi N, Kaddourah A, Abu-Hasan M, Al-Adba B, et al. Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome. Journal of Clinical Immunology. 2026;46(1). doi:10.1007/s10875-026-02056-4
BibTeX
@article{Hamad2026,
author = {Hamad, Sara G and Makhlouf, Melanie and Agrebi, Nourhen and Kaddourah, Ahmad and Abu-Hasan, Mutasim and Al-Adba, Buthaina and Sadoun, Ameera and Hubrack, Satanay Z and Aamer, Waleed and Segura, Mayra L Ruiz Tejada and Scialdone, Antonio and Machaca, Khaled and Saraiva, Luis R and Bout-Tabaku, Sharon and Lo, Bernice},
title = {Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome},
journal = {Journal of Clinical Immunology},
year = {2026},
volume = {46},
number = {1},
doi = {10.1007/s10875-026-02056-4}
}
EUVIMED